drugset
drugset / Trial / NCT03757754

HPPH Photodynamic Therapy for Patients With Esophageal Cancer

NCT03757754 ↗

Phase 1 Unknown 30 enrolled Zhejiang Hisun Pharmaceutical Co. Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

Phase I study was to investigate the safety and tolerability of the photosensitizer (PS) 2-\[1-hexyloxyethyl\]-2-devinyl pyropheophorbide-a (HPPH) for injection in patients with Esophageal Cancer. It was to characterize the pharmacokinetics of HPPH and efficacy of HPPH.

Timeline

Start
2015-06-03
Primary completion
2019-01-20
Completion
2019-05-27

Drugs

EvaluationDrugModalityDoseRoute
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 2.5 mg/m2 Intravenous
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 3 mg/m2 Intravenous
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 3.5 mg/m2 Intravenous
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 4 mg/m2 Intravenous
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 5 mg/m2 Intravenous
Subject 2-(1-HEXYLOXYETHYL)-2-DEVINYL PYROPHEOPHORBIDE-A Unknown 6 mg/m2 Intravenous

Indications

esophageal cancer